Chebib FT, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies. Kidney Med. 2023 Jun;5(6):100639. doi: 10.1016/j.xkme.2023.100639
Sauchelli S, Rogers PJ, Fry G, Hamilton-Shield JP. Preference for high carbohydrate foods does not change for children and adolescents in insulin-induced hypoglycemia. BMJ Open Diabetes Res Care. 2022 Nov 8;10(6). doi: 10.1136/bmjdrc-2022-003065
Sauchelli S, Bradley J, England C, Searle A, Whitmarsh A. Exploring support needs of people living with diabetes during the coronavirus COVID-19 pandemic: insights from a UK survey. BMJ Open Diabetes Res Care. 2021 Jun;9(1):e002162. doi: 10.1136/bmjdrc-2021-002162
Cainzos-Achirica M, Bilal U, Kapoor K, Quispe Ayala R, McEvoy JW, Pladevall-Vila M, Blumenthal RS, Blaha MJ. Methodological issues in nutritional epidemiology research–sorting through the confusion. Current Cardiovascular Risk Reports. 2018 Feb;12:4. doi: 10.1007/s12170-018-0567-8
Schwab P, Saundankar V, Bouchard J, Wintfeld N, Suehs B, Moretz C, Allen E, DeLuzio A. Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications, and healthcare costs. BMJ Open Diabetes Res Care. 2016 Feb 18;4(1):e000099. doi: 10.1136/bmjdrc-2015-000099
Brubaker L, Richter HE, Barber MD, Hsu Y, Rahn DD, Menefee S, Visco A, Spino C, Martin S, Meikle SF. Pelvic floor disorders clinical trials: participant recruitment and retention. Int Urogynecol J. 2013 Jan 1;24(1):73-9.
Alwin J, Brodtkorb T. Could the choice of patient versus proxy ratings for assessing quality of life in dementia affect resource allocation in health care? Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2012;13(1):25-31.
Zaniolo O, Wolowacz SE, Pradelli L. Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l'Italia. Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2010;11(2):91-101.
Zaniolo O, Wolowacz SE, Pradelli L. Economic performance of dabigatran etexilate for primary VTE prevention following total hip and knee replacement surgery in Italy [Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l'Italia]. Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2010;11(2):91-101.